Innovative Precision Oncology 4D Path's advanced platform, QPOR™, offers highly accurate predictions of tumor responses from routine biopsy images, presenting an opportunity to partner with hospitals and clinics seeking next-generation diagnostic tools to improve personalized cancer care.

Growing Market Presence The company's active participation in major events like ASCO 2025 and its recent unveiling of groundbreaking predictive biomarkers demonstrate increasing visibility and credibility within the oncology community, opening doors for strategic collaborations and increased sales channels.

Strong Regulatory Validation Receiving an FDA Breakthrough Device Designation boosts trust among healthcare providers and payers, positioning 4D Path’s solutions as clinically valuable and potentially reimbursable, which can accelerate adoption and sales.

Collaborative Research Momentum Ongoing partnerships with academic institutions such as the University of Leeds, supported by positive clinical results, provide a foundation for expanding into new research collaborations and licensing opportunities within the oncology space.

Sustainable Growth Potential With a funding of $13 million and a revenue range of up to $10 million, 4D Path shows financial stability and growth potential, making it an attractive prospect for investors and enterprise customers aiming to integrate innovative diagnostic solutions into their treatment workflows.